{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:15:40Z","timestamp":1792293340524,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1124\/jpet.106.111344","type":"journal-article","created":{"date-parts":[[2007,2,8]],"date-time":"2007-02-08T20:50:30Z","timestamp":1170967830000},"page":"509-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":314,"title":["(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2 R,3 S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme\/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1\u03b2 and IL-18"],"prefix":"10.1016","volume":"321","author":[{"given":"Woods","family":"Wannamaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Namchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamella","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Charifson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Germann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kuida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.R.","family":"Randle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.106.111344_bib1","doi-asserted-by":"crossref","unstructured":"Antonopoulos C, Cumberbatch M, Dearman RJ, Daniel RJ, Kimber I, and Groves RW (2001) Functional caspase-1 is required for Langerhans cell migration and optimal contact sensitization in mice. J Immunol 166: 3672\u20133677.","DOI":"10.4049\/jimmunol.166.6.3672"},{"key":"10.1124\/jpet.106.111344_bib2","doi-asserted-by":"crossref","unstructured":"Askenase PW (2001) Yes T cells, but three different T cells (alphabeta, gammadelta and NK T cells), and also B-1 cells mediate contact sensitivity. Clin Exp Immunol 125: 345\u2013350.","DOI":"10.1046\/j.1365-2249.2001.01619.x"},{"key":"10.1124\/jpet.106.111344_bib3","doi-asserted-by":"crossref","unstructured":"Braddock M and Quinn A (2004) Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 3: 330\u2013339.","DOI":"10.1038\/nrd1342"},{"key":"10.1124\/jpet.106.111344_bib4","doi-asserted-by":"crossref","unstructured":"Campbell IK, O\u2019Donnell K, Lawlor KE, and Wicks IP (2001) Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Investig 107: 1519\u20131527.","DOI":"10.1172\/JCI12724"},{"key":"10.1124\/jpet.106.111344_bib5","doi-asserted-by":"crossref","unstructured":"Covert MW, Leung TH, Gaston JE, and Baltimore D (2005) Achieving stability of lipopolysaccharide-induced NF-\u03baB activation. Science (Wash DC) 309: 1854\u20131857.","DOI":"10.1126\/science.1112304"},{"key":"10.1124\/jpet.106.111344_bib6","doi-asserted-by":"crossref","unstructured":"Cumberbatch M, Dearman RJ, Antonopoulos C, Groves RW, and Kimber I (2001) Interleukin (IL)-18 induces Langerhans cell migration by a tumour necrosis factor-\u03b1- and IL-1\u03b2-dependent mechanism. Immunology 102: 323\u2013330.","DOI":"10.1046\/j.1365-2567.2001.01187.x"},{"key":"10.1124\/jpet.106.111344_bib7","unstructured":"Dinarello CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20: S1\u2013S13."},{"key":"10.1124\/jpet.106.111344_bib8","doi-asserted-by":"crossref","unstructured":"Earnshaw WC, Martins LM, and Kaufmann SH (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68: 383\u2013424.","DOI":"10.1146\/annurev.biochem.68.1.383"},{"key":"10.1124\/jpet.106.111344_bib9","doi-asserted-by":"crossref","unstructured":"Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, et al. (1989) Antibodies to cachectin\/tumor necrosis factor reduce interleukin 1\u03b2 and interleukin 6 appearance during lethal bacteremia. J Exp Med 170: 1627\u20131633.","DOI":"10.1084\/jem.170.5.1627"},{"key":"10.1124\/jpet.106.111344_bib10","doi-asserted-by":"crossref","unstructured":"Fitzgerald AA, LeClercq SA, Yan A, Homik JE, and Dinarello CA (2005) Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease. Arthritis Rheum 52: 1794\u20131803.","DOI":"10.1002\/art.21061"},{"key":"10.1124\/jpet.106.111344_bib11","doi-asserted-by":"crossref","unstructured":"Fox T, de Miguel E, Mort JS, and Storer AC (1992) Potent slow-binding inhibition of cathepsin B by its propeptide. Biochemistry 31: 12571\u201312576.","DOI":"10.1021\/bi00165a005"},{"key":"10.1124\/jpet.106.111344_bib12","doi-asserted-by":"crossref","unstructured":"Goldring SR and Gravallese EM (2000) Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 12: 195\u2013199.","DOI":"10.1097\/00002281-200005000-00006"},{"key":"10.1124\/jpet.106.111344_bib13","doi-asserted-by":"crossref","unstructured":"Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K, Yamamura K, Miyazaki J, Young HA, and Oizumi K (2001) Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 166: 7014\u20137018.","DOI":"10.4049\/jimmunol.166.12.7014"},{"key":"10.1124\/jpet.106.111344_bib14","doi-asserted-by":"crossref","unstructured":"Iwakura Y (2002) Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev 13: 341\u2013355.","DOI":"10.1016\/S1359-6101(02)00021-7"},{"key":"10.1124\/jpet.106.111344_bib15","doi-asserted-by":"crossref","unstructured":"Joosten LA, Helsen MM, van de Loo FA, and van den Berg WB (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice. A comparative study using anti-TNF\u03b1, anti-IL-1\u03b1\/\u03b2, and IL-1Ra. Arthritis Rheum 39: 797\u2013809.","DOI":"10.1002\/art.1780390513"},{"key":"10.1124\/jpet.106.111344_bib16","doi-asserted-by":"crossref","unstructured":"Ku G, Faust T, Lauffer LL, Livingston DJ, and Harding MW (1996) Interleukin-1\u03b2 converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 8: 377\u2013386.","DOI":"10.1006\/cyto.1996.0052"},{"key":"10.1124\/jpet.106.111344_bib17","unstructured":"Ku G, Ford P, Raybuck SA, Harding MW, and Randle JCR (2001) Selective interleukin-1\u03b2 converting enzyme (ICE\/caspase-1) inhibition with pralnacasan (HMR 3480\/VX-740) reduces inflammation and joint destruction in murine type II collagen-induced arthritis (CIA). Arthritis Rheum 44: S241."},{"key":"10.1124\/jpet.106.111344_bib18","doi-asserted-by":"crossref","unstructured":"Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, and Flavell RA (1995) Altered cytokine export and apoptosis in mice deficient in interleukin-1\u03b2 converting enzyme. Science (Wash DC) 267: 2000\u20132003.","DOI":"10.1126\/science.7535475"},{"key":"10.1124\/jpet.106.111344_bib19","doi-asserted-by":"crossref","unstructured":"Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, et al. (1995) Mice deficient in IL-1\u03b2-converting enzyme are defective in production of mature IL-1\u03b2 and resistant to endotoxic shock. Cell 80: 401\u2013411.","DOI":"10.1016\/0092-8674(95)90490-5"},{"key":"10.1124\/jpet.106.111344_bib20","doi-asserted-by":"crossref","unstructured":"Loher F, Bauer C, Landauer N, Schmall K, Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S, and Eigler A (2004) The interleukin-1\u03b2-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 308: 583\u2013590.","DOI":"10.1124\/jpet.103.057059"},{"key":"10.1124\/jpet.106.111344_bib21","doi-asserted-by":"crossref","unstructured":"Martinon F and Tschopp J (2004) Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117: 561\u2013574.","DOI":"10.1016\/j.cell.2004.05.004"},{"key":"10.1124\/jpet.106.111344_bib22","doi-asserted-by":"crossref","unstructured":"Mori L, Iselin S, De Libero G, and Lesslauer W (1996) Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 157: 3178\u20133182.","DOI":"10.4049\/jimmunol.157.7.3178"},{"key":"10.1124\/jpet.106.111344_bib23","doi-asserted-by":"crossref","unstructured":"Murray N, Zoerkler N, Brown T, and Bonhomme Y (1994) LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol 16: 675\u2013683.","DOI":"10.1016\/0192-0561(94)90141-4"},{"key":"10.1124\/jpet.106.111344_bib24","doi-asserted-by":"crossref","unstructured":"Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, and Caughman SW (1999) Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with proinflammatory mediators and dinitrochlorobenzene. J Investig Dermatol 113: 766\u2013772.","DOI":"10.1046\/j.1523-1747.1999.00750.x"},{"key":"10.1124\/jpet.106.111344_bib25","doi-asserted-by":"crossref","unstructured":"Neidel J, Schulze M, and Lindschau J (1995) Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 44: 217\u2013221.","DOI":"10.1007\/BF01782262"},{"key":"10.1124\/jpet.106.111344_bib26","doi-asserted-by":"crossref","unstructured":"Pascual V, Allantaz F, Arce E, Punaro M, and Branchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201: 1479\u20131486.","DOI":"10.1084\/jem.20050473"},{"key":"10.1124\/jpet.106.111344_bib27","doi-asserted-by":"crossref","unstructured":"Rioja I, Bush KA, Buckton JB, Dickson MC, and Life PF (2004) Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol 137: 65\u201373.","DOI":"10.1111\/j.1365-2249.2004.02499.x"},{"key":"10.1124\/jpet.106.111344_bib28","doi-asserted-by":"crossref","unstructured":"Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, and van den Berg W (2003) Pralnacasan, an inhibitor of interleukin-1\u03b2 converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthr Cartil 11: 738\u2013746.","DOI":"10.1016\/S1063-4584(03)00153-5"},{"key":"10.1124\/jpet.106.111344_bib29","doi-asserted-by":"crossref","unstructured":"Saijo S, Asano M, Horai R, Yamamoto H, and Iwakura Y (2002) Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum 46: 533\u2013544.","DOI":"10.1002\/art.10172"},{"key":"10.1124\/jpet.106.111344_bib30","doi-asserted-by":"crossref","unstructured":"Smith DJ, McGuire MJ, Tocci MJ, and Thiele DL (1997) IL-1\u03b2 convertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas-dependent or Fas-independent CTL effector mechanisms. J Immunol 158: 163\u2013170.","DOI":"10.4049\/jimmunol.158.1.163"},{"key":"10.1124\/jpet.106.111344_bib31","doi-asserted-by":"crossref","unstructured":"Stack JH, Beaumont K, Larsen PD, Straley KS, Henkel GW, Randle JCR, and Hoffman HM (2005) ICE\/Caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from FCAS patients. J Immunol 175: 2630\u20132634.","DOI":"10.4049\/jimmunol.175.4.2630"},{"key":"10.1124\/jpet.106.111344_bib32","doi-asserted-by":"crossref","unstructured":"Stoll S, Jonuleit H, Schmitt E, Muller G, Yamauchi H, Kurimoto M, Knop J, and Enk AH (1998) Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 28: 3231\u20133239.","DOI":"10.1002\/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.3.CO;2-H"},{"key":"10.1124\/jpet.106.111344_bib33","doi-asserted-by":"crossref","unstructured":"Thalappilly S, Sadasivam S, Radha V, and Swarup G (2006) Involvement of caspase 1 and its activator Ipaf upstream of mitochondrial events in apoptosis. FEBS J. 273: 2766\u20132778.","DOI":"10.1111\/j.1742-4658.2006.05293.x"},{"key":"10.1124\/jpet.106.111344_bib34","doi-asserted-by":"crossref","unstructured":"Ting JP, Kastner DL, and Hoffman HM (2006) CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 6: 183\u2013195.","DOI":"10.1038\/nri1788"},{"key":"10.1124\/jpet.106.111344_bib35","unstructured":"van den Berg WB (2002) Is there a rationale for combined TNF and IL-1 blocking in arthritis? Clin Exp Rheumatol 20: S21\u2013S25."},{"key":"10.1124\/jpet.106.111344_bib36","doi-asserted-by":"crossref","unstructured":"Wang B, Feliciani C, Howell BG, Freed I, Cai Q, Watanabe H, and Sauder DN (2002) Contribution of Langerhans cell-derived IL-18 to contact hypersensitivity. J Immunol 168: 3303\u20133308.","DOI":"10.4049\/jimmunol.168.7.3303"},{"key":"#cr-split#-10.1124\/jpet.106.111344_bib37.1","unstructured":"Wannamaker M and Davies R (2001) inventors"},{"key":"#cr-split#-10.1124\/jpet.106.111344_bib37.2","unstructured":"Vertex Pharma, assignee. Prodrug of an ICE inhibitor. World Patent WO0190063. 2001 Nov 29"},{"key":"10.1124\/jpet.106.111344_bib38","doi-asserted-by":"crossref","unstructured":"Wooley PH, Dutcher J, Widmer MB, and Gillis S (1993) Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 6602\u20136607.","DOI":"10.4049\/jimmunol.151.11.6602"},{"key":"10.1124\/jpet.106.111344_bib39","doi-asserted-by":"crossref","unstructured":"Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, and Nakanishi K (1998) IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-\u03b3 production. J Immunol 161: 3400\u20133407.","DOI":"10.4049\/jimmunol.161.7.3400"},{"key":"10.1124\/jpet.106.111344_bib40","doi-asserted-by":"crossref","unstructured":"Zepter K, Haffner A, Soohoo LF, De Luca D, Tang HP, Fisher P, Chavinson J, and Elmets CA (1997) Induction of biologically active IL-1\u03b2-converting enzyme and mature IL-1\u03b2 in human keratinocytes by inflammatory and immunologic stimuli. J Immunol 159: 6203\u20136208.","DOI":"10.4049\/jimmunol.159.12.6203"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524338224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524338224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.106.111344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:14:59Z","timestamp":1739985299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524338224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0022356524338224"],"URL":"https:\/\/doi.org\/10.1124\/jpet.106.111344","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2 R,3 S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme\/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1\u03b2 and IL-18","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.106.111344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}